Research Supports Risks Alleged In Xarelto Lawsuit Cases Consolidated Into MDL 2592

July 01, 2016 – – TheProductLawyers.com reports on the latest support offered to the ongoing cases against Janssen Pharmaceuticals and Bayer AG. Claims commonly allege that the plaintiffs were exposed to a substantially increased risk for catastrophic bleeding episodes while taking Xarelto—a new-generation anticoagulant produced and marketed by the pharmaceutical companies. In the past year, several studies have been published, which would appear to support those claims.

In April of 2015, a study chronicling the extended medical histories of nearly 46,000 patients currently engaged in an anticoagulant regimen was published in the British Medical Journal (BMJ). Researchers noted that patients who weaned off of warfarin—a traditional anticoagulant—and replaced it with Xarelto may have a two-fold increased risk in the probability of suffering a gastrointestinal bleeding event.

In another instance, Drs. Judy Hun and John C. Hwang noticed a troubling co-occurrence of circumstances in their shared practice. Intent upon discovering the cause of vitreous hemorrhages or uncontrolled eye bleeds, they designed an empirical study. Closely observing patients ranging in age from 70 to 89—all of whom had made the progressive switch from more traditional anticoagulants to Xarelto—they noted a substantive trend. They published the complete findings of their study in the June 2015 edition of JAMA Ophthalmology, noting that, “In all cases, an acute vitreous hemorrhage occurred shortly after rivaroxaban (Xarelto) treatment was initiated.”

Late last year, more than 2,800 federal cases against Xarelto and its manufacturers were consolidated into the multidistrict litigation (MDL) No. 2592. Among the plaintiffs, the common cause against Xarelto is clear in their claims. The cases allege that taking the new-generation anticoagulant substantially increased their risk of a catastrophic bleeding event. Many parties represented are seeking reparations for injury or even death as a result of these risks. Judge Eldon Fallon has been appointed to preside over the MDL in the Eastern District Court of Louisiana. It is clear that, as the cases move closer to a court date, more lawsuits are likely to be combined with the MDL.

The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-997-3792.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60011136